Cubist Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of pharmaceutical products. Cubist offers products and product candidates are used in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. The Company’s product CUBICIN is marketed at CUBICIN in the United States. DIFICID is approved in the United States for the treatment of Clostridium difficile-associated diarrhea (CDAD); it is also approved in the European Union, Canada and Australia for similar indications. ENTEREG is approved in the United States for acceleration of upper and lower gastrointestinal (GI) recovery following surgeries. Surotomycin is in Phase 3 clinical trials and is aimed at CDAD. For Bevenopran, the Company is engaged in a Phase 3 long-term safety study.